Gheorghe Doros is Professor of Biostatistics and director of the Biostatistics Consulting Group. He received his PhD in Statistics from Yale University and joined BUSPH’s Department of Biostatistics in 2006 after spending two years at Eli Lilly, as a member of that company's Drug Discovery and Toxicology department. Dr. Doros’s research on methodological approaches and strategies has been concentrated in the area of clinical trials, more specifically on Bayesian approaches to clinical trials and the area of placebo response. The outcome of his work has been a corner stone in developing a host of collaborations with outstanding faculty, clinicians, and researchers at the Boston University Medical Campus and at other institutions. These productive collaborations have resulted in several federally funded grants. Dr. Doros authored and co-authored many peer-reviewed publications of original and innovative research which has had a major impact on the field. On the majority of publications, Dr. Doros is the lead statistician author. He has demonstrated a continuing record of multidisciplinary research that has had a major impact on the rapidly changing field. His publications on clinical trials; most proposing the design, analysis and new methodologies or of significant contributions to this field. Dr. Doros is a very active and effective teacher and mentor in the department of Biostatistics. His teaching philosophy is to pursue an active approach to learning and to engage students to think critically. He taught core and elective courses for Master and PhD-level courses. The excellent course evaluations he has received attest to his ability in engaging students in active learning. Dr. Doros has been awarded the Excellence in Teaching award three times in three years. On a national level, Dr. Doros has served as an Associate Editor for the BioMed Central’s journal “Trials” and as a reviewer for a number of other academic journals. He served as a member of the merit review subcommittee for Epidemiology of the Department of Veteran Affairs and a member of NHLBI Ancillary Studies in Clinical Trials between 2012 and 2014. He has served as a statistical expert on a number of Independent Data Monitoring Committees (IDMC) for clinical trials and clinical programs. He serves as a senior consultant on multicenter trials and/or programs for the following organizations: Pfizer, Takeda, Avanir, Sarepta, and Boston Children's Hospital.